Mario Gabelli's BMY Position Overview
Mario Gabelli (via Gamco Investors, Inc. Et Al) currently holds 100,794 shares of Bristol-Myers Squibb Company (BMY) worth $4.55 M, representing 0.04% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Mario Gabelli has maintained a long-term strategic position in BMY, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2019, adding 139,692 shares. Largest reduction occurred in Q2 2020, reducing 292,473 shares.
Analysis based on 13F filings available since 2013 Q2
Mario Gabelli's Bristol-Myers Squibb Company (BMY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bristol-Myers Squibb Company (BMY) Trades by Mario Gabelli
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +804,626 | Add 0.00% | 804,625 | $44.69 |
| Q3 2013 | -34,725 | Reduce 4.32% | 769,900 | $46.28 |
| Q4 2013 | -39,129 | Reduce 5.08% | 730,771 | $53.15 |
| Q1 2014 | -43,986 | Reduce 6.02% | 686,785 | $51.95 |
| Q2 2014 | -12,100 | Reduce 1.76% | 674,685 | $48.51 |
| Q3 2014 | +25,570 | Add 3.79% | 700,255 | $51.18 |
| Q4 2014 | +9,460 | Add 1.35% | 709,715 | $59.03 |
| Q1 2015 | -5,290 | Reduce 0.75% | 704,425 | $64.50 |
| Q2 2015 | -25,789 | Reduce 3.66% | 678,636 | $66.54 |
| Q3 2015 | -27,219 | Reduce 4.01% | 651,417 | $59.20 |
| Q4 2015 | -12,062 | Reduce 1.85% | 639,355 | $68.79 |
| Q1 2016 | +14,650 | Add 2.29% | 654,005 | $63.88 |
| Q2 2016 | -34,378 | Reduce 5.26% | 619,627 | $73.55 |
| Q3 2016 | -62,700 | Reduce 10.12% | 556,927 | $53.92 |
| Q4 2016 | -33,255 | Reduce 5.97% | 523,672 | $58.44 |
| Q1 2017 | -10,625 | Reduce 2.03% | 513,047 | $54.38 |
| Q2 2017 | -46,965 | Reduce 9.15% | 466,082 | $55.72 |
| Q3 2017 | +1,785 | Add 0.38% | 467,867 | $63.74 |
| Q4 2017 | -59,265 | Reduce 12.67% | 408,602 | $61.28 |
| Q1 2018 | +57,577 | Add 14.09% | 466,179 | $63.25 |
| Q2 2018 | +90,424 | Add 19.40% | 556,603 | $55.34 |
| Q3 2018 | -16,500 | Reduce 2.96% | 540,103 | $62.08 |
| Q4 2018 | -40,850 | Reduce 7.56% | 499,253 | $51.98 |
| Q1 2019 | -573 | Reduce 0.11% | 498,680 | $47.71 |
| Q2 2019 | -111,242 | Reduce 22.31% | 387,438 | $45.35 |
| Q3 2019 | -58,218 | Reduce 15.03% | 329,220 | $50.71 |
| Q4 2019 | +139,692 | Add 42.43% | 468,912 | $64.19 |
| Q1 2020 | +48,138 | Add 10.27% | 517,050 | $55.74 |
| Q2 2020 | -292,473 | Reduce 56.57% | 224,577 | $58.80 |
| Q3 2020 | -16,915 | Reduce 7.53% | 207,662 | $60.29 |
| Q4 2020 | -18,230 | Reduce 8.78% | 189,432 | $62.03 |
| Q1 2021 | -7,008 | Reduce 3.70% | 182,424 | $63.13 |
| Q2 2021 | -6,769 | Reduce 3.71% | 175,655 | $66.82 |
| Q3 2021 | +6,300 | Add 3.59% | 181,955 | $59.17 |
| Q4 2021 | -14,610 | Reduce 8.03% | 167,345 | $62.35 |
| Q1 2022 | -10,091 | Reduce 6.03% | 157,254 | $73.03 |
| Q2 2022 | -15,783 | Reduce 10.04% | 141,471 | $77.00 |
| Q3 2022 | -706 | Reduce 0.50% | 140,765 | $71.09 |
| Q4 2022 | -5,421 | Reduce 3.85% | 135,344 | $71.95 |
| Q1 2023 | -2,287 | Reduce 1.69% | 133,057 | $69.31 |
| Q2 2023 | -8,337 | Reduce 6.27% | 124,720 | $63.95 |
| Q3 2023 | -1,781 | Reduce 1.43% | 122,939 | $58.04 |
| Q4 2023 | -4,417 | Reduce 3.59% | 118,522 | $51.31 |
| Q1 2024 | -1,957 | Reduce 1.65% | 116,565 | $54.23 |
| Q2 2024 | -5,126 | Reduce 4.40% | 111,439 | $41.53 |
| Q3 2024 | -545 | Reduce 0.49% | 110,894 | $51.74 |
| Q4 2024 | -6,311 | Reduce 5.69% | 104,583 | $56.56 |
| Q1 2025 | -5,260 | Reduce 5.03% | 99,323 | $60.99 |
| Q2 2025 | +2,778 | Add 2.80% | 102,101 | $46.29 |
| Q3 2025 | -1,307 | Reduce 1.28% | 100,794 | $45.10 |
Mario Gabelli's Bristol-Myers Squibb Company Investment FAQs
Mario Gabelli first purchased Bristol-Myers Squibb Company (BMY) in Q2 2013, acquiring 804,625 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mario Gabelli has held Bristol-Myers Squibb Company (BMY) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mario Gabelli's largest addition to Bristol-Myers Squibb Company (BMY) was in Q2 2013, adding 804,625 shares worth $35.96 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Mario Gabelli's firm, Gamco Investors, Inc. Et Al, owns 100,794 shares of Bristol-Myers Squibb Company (BMY), valued at approximately $4.55 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Bristol-Myers Squibb Company (BMY) represents approximately 0.04% of Mario Gabelli's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mario Gabelli's peak holding in Bristol-Myers Squibb Company (BMY) was 804,625 shares, as reported at the end of Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.